{"pmid":32329877,"title":"SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.","text":["SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.","SARS-CoV-2 is responsible for the outbreak of severe respiratory illness (COVID-19) in Wuhan City, China and is now spreading rapidly throughout the world. The prompt outbreak of COVID-19 and its quick spread without any controllable measure defines the severity of the situation. In this crisis, a collective pool of knowledge about the advancement of clinical diagnostic and management for COVID-19 is a prerequisite. Here, we summarize all the available updates on the multidisciplinary approaches for the advancement of diagnosis and proposed therapeutic strategies for COVID-19. Moreover, the review discusses different aspects of the COVID-19, including its epidemiology; incubation period; the general clinical features of patients; the clinical features of intensive care unit (ICU) patients; SARS-CoV-2 infection in the presence of co-morbid diseases and the clinical features of pediatric patients infected with the SARS-CoV-2. Advances in various diagnostic approaches, such as the use of real-time polymerase chain reaction (RT-PCR), chest radiography, and computed tomography (CT) imaging; and other modern diagnostic methods, for this infection have been highlighted. However, due to the unavailability of adequate evidence, presently there are no officially approved drugs or vaccines available against SARS-CoV-2. Additionally, we have discussed various therapeutic strategies for COVID-19 under different categories, like the possible treatment plans with drug (antiviral drugs and anti-cytokines) therapy for disease prevention. Lastly, potentials candidates for the vaccines against SARS-CoV-2 infection have been described. Collectively, the review provides an overview of the SARS-CoV-2 infection outbreak along with the recent advancements and strategies for diagnosis and therapy of COVID-19.","Eur Rev Med Pharmacol Sci","Chakraborty, C","Sharma, A R","Sharma, G","Bhattacharya, M","Lee, S S","32329877"],"abstract":["SARS-CoV-2 is responsible for the outbreak of severe respiratory illness (COVID-19) in Wuhan City, China and is now spreading rapidly throughout the world. The prompt outbreak of COVID-19 and its quick spread without any controllable measure defines the severity of the situation. In this crisis, a collective pool of knowledge about the advancement of clinical diagnostic and management for COVID-19 is a prerequisite. Here, we summarize all the available updates on the multidisciplinary approaches for the advancement of diagnosis and proposed therapeutic strategies for COVID-19. Moreover, the review discusses different aspects of the COVID-19, including its epidemiology; incubation period; the general clinical features of patients; the clinical features of intensive care unit (ICU) patients; SARS-CoV-2 infection in the presence of co-morbid diseases and the clinical features of pediatric patients infected with the SARS-CoV-2. Advances in various diagnostic approaches, such as the use of real-time polymerase chain reaction (RT-PCR), chest radiography, and computed tomography (CT) imaging; and other modern diagnostic methods, for this infection have been highlighted. However, due to the unavailability of adequate evidence, presently there are no officially approved drugs or vaccines available against SARS-CoV-2. Additionally, we have discussed various therapeutic strategies for COVID-19 under different categories, like the possible treatment plans with drug (antiviral drugs and anti-cytokines) therapy for disease prevention. Lastly, potentials candidates for the vaccines against SARS-CoV-2 infection have been described. Collectively, the review provides an overview of the SARS-CoV-2 infection outbreak along with the recent advancements and strategies for diagnosis and therapy of COVID-19."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Chakraborty, C","Sharma, A R","Sharma, G","Bhattacharya, M","Lee, S S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329877","week":"202017|Apr 20 - Apr 26","doi":"10.26355/eurrev_202004_20871","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664996914752389121,"score":8.518259,"similar":[{"pmid":32172228,"title":"Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","text":["Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance.","Clin Chem Lab Med","Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario","32172228"],"abstract":["A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32172228","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0285","keywords":["covid-19","coronavirus","diagnosis","reverse transcription polymerase chain reaction (rt-pcr)"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664640874673340418,"score":345.3095},{"pmid":32291374,"title":"The Importance of Chest CT Scan in COVID-19.","text":["The Importance of Chest CT Scan in COVID-19.","The coronavirus disease 2019 (COVID-19) is a highly transmissible acute respiratory disease that is caused by the Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2), a beta coronavirus first discovered in Wuhan, China, in late 2019. COVID-19 has been spreading swiftly globally, and as of March 2020, has been officially declared a pandemic by the World Health Organization (WHO). One of the challenges in managing COVID-19 is the identification of a swift, accessible, and reliable diagnostic modality that could serve as an alternative to a reverse-transcriptase polymerase chain reaction (RT-PCR). As of the writing of this paper, RT-PCR is still the recommended tool in diagnosing COVID-19, but the notion of a more prompt and accurate diagnostic tool is a possibility worth looking into. The objective of this case study is to investigate the importance and utility of chest computed tomography (CT) in the diagnosis of COVID-19, as increasing pieces of evidence suggest that chest CT could prove useful in the clinical pathway in diagnosing COVID-19.","Acta Med Indones","Tenda, Eric Daniel","Yulianti, Mira","Asaf, Moses Mazmur","Yunus, Reyhan Eddy","Septiyanti, Wita","Wulani, Vally","Pitoyo, Ceva Wicaksono","Rumende, Cleopas Martin","Setiati, Siti","32291374"],"abstract":["The coronavirus disease 2019 (COVID-19) is a highly transmissible acute respiratory disease that is caused by the Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2), a beta coronavirus first discovered in Wuhan, China, in late 2019. COVID-19 has been spreading swiftly globally, and as of March 2020, has been officially declared a pandemic by the World Health Organization (WHO). One of the challenges in managing COVID-19 is the identification of a swift, accessible, and reliable diagnostic modality that could serve as an alternative to a reverse-transcriptase polymerase chain reaction (RT-PCR). As of the writing of this paper, RT-PCR is still the recommended tool in diagnosing COVID-19, but the notion of a more prompt and accurate diagnostic tool is a possibility worth looking into. The objective of this case study is to investigate the importance and utility of chest computed tomography (CT) in the diagnosis of COVID-19, as increasing pieces of evidence suggest that chest CT could prove useful in the clinical pathway in diagnosing COVID-19."],"journal":"Acta Med Indones","authors":["Tenda, Eric Daniel","Yulianti, Mira","Asaf, Moses Mazmur","Yunus, Reyhan Eddy","Septiyanti, Wita","Wulani, Vally","Pitoyo, Ceva Wicaksono","Rumende, Cleopas Martin","Setiati, Siti"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291374","week":"202016|Apr 13 - Apr 19","keywords":["internal medicine","radiology","respiratory medicine"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636192509919232,"score":284.80637},{"pmid":32324359,"title":"[Diagnostic steps and estimation of disease prognosis in COVID-19-infected patients].","text":["[Diagnostic steps and estimation of disease prognosis in COVID-19-infected patients].","In December 2019, a new coronavirus outbreak hit his head in Wuhan, China. The identified pathogen is a new coronavirus named \"severe acute respiratory syndrome coronavirus 2,\" or SARS-CoV-2, and the respiratory syndrome it elicits was named \"coronavirus disease 2019,\" or COVID-19. The World Health Organization (WHO) classified the epidemic as a pandemic in March 2020. We reviewed the currently available international literature on the COVID-19 epidemic. In this paper, we summarize the relevant information for the diagnosis and prognosis of the new coronavirus. Details of the anamnestic factors and initial test results required to raise a clinical suspicion, the method of microbiological sampling, the basic information on the molecular diagnostic test - the 'gold-standard' real-time 'reverse transcriptase polymerase chain reaction (RT-PCR) - in particular the diagnostic current public health regulations for testing. We also place emphasis on the parameters of high-risk patients and how to identify them. The COVID-19 pandemic may also have significant epidemiological and health consequences in Hungary. In addition to epidemiological measures to slow down the epidemic, the timely identification and adequate hospital care of already infected individuals is also a key issue in terms of mortality. The chances of critically ill patients can only be improved with high-quality, careful intensive care, and to be able to provide the best, it is useful to use the experience of medical colleagues already working in endemic countries. Orv Hetil. 2020; 160 (17): 667-671.","Orv Hetil","Korsos, Anita","Kupcsulik, Szilvia","Lovas, Andras","Hankovszky, Peter","Molnar, Tamas","Szabo, Zsolt","Babik, Barna","32324359"],"abstract":["In December 2019, a new coronavirus outbreak hit his head in Wuhan, China. The identified pathogen is a new coronavirus named \"severe acute respiratory syndrome coronavirus 2,\" or SARS-CoV-2, and the respiratory syndrome it elicits was named \"coronavirus disease 2019,\" or COVID-19. The World Health Organization (WHO) classified the epidemic as a pandemic in March 2020. We reviewed the currently available international literature on the COVID-19 epidemic. In this paper, we summarize the relevant information for the diagnosis and prognosis of the new coronavirus. Details of the anamnestic factors and initial test results required to raise a clinical suspicion, the method of microbiological sampling, the basic information on the molecular diagnostic test - the 'gold-standard' real-time 'reverse transcriptase polymerase chain reaction (RT-PCR) - in particular the diagnostic current public health regulations for testing. We also place emphasis on the parameters of high-risk patients and how to identify them. The COVID-19 pandemic may also have significant epidemiological and health consequences in Hungary. In addition to epidemiological measures to slow down the epidemic, the timely identification and adequate hospital care of already infected individuals is also a key issue in terms of mortality. The chances of critically ill patients can only be improved with high-quality, careful intensive care, and to be able to provide the best, it is useful to use the experience of medical colleagues already working in endemic countries. Orv Hetil. 2020; 160 (17): 667-671."],"journal":"Orv Hetil","authors":["Korsos, Anita","Kupcsulik, Szilvia","Lovas, Andras","Hankovszky, Peter","Molnar, Tamas","Szabo, Zsolt","Babik, Barna"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324359","week":"202017|Apr 20 - Apr 26","doi":"10.1556/650.2020.31815","keywords":["covid-19","rt-pcr","sars-cov-2","diagnostic testing high-risk patient","diagnosztika","jarvany","magas rizikoju beteg","novel coronavirus","outbreak","pandemic","pandemia","prognosis","prognozis","uj koronavirus"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"locations":["Wuhan","China","Hungary"],"countries":["China","Hungary"],"countries_codes":["CHN|China","HUN|Hungary"],"_version_":1664895932644196352,"score":267.13043},{"pmid":32316618,"title":"Novel Coronavirus: Current Understanding of Clinical Features, Diagnosis, Pathogenesis, and Treatment Options.","text":["Novel Coronavirus: Current Understanding of Clinical Features, Diagnosis, Pathogenesis, and Treatment Options.","Since December 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in devastating consequences worldwide and infected more than 350,000 individuals and killed more than 16,000 people. SARS-CoV-2 is the seventh member of the coronavirus family to affect humans. Symptoms of COVID-19 include fever (88%), cough (68%), vomiting (5%) and diarrhoea (3.7%), and transmission of SARS-CoV-2 is thought to occur from human to human via respiratory secretions released by the infected individuals when coughing and sneezing. COVID-19 can be detected through computed tomography scans and confirmed through molecular diagnostics tools such as polymerase chain reaction. Currently, there are no effective treatments against SARS-CoV-2, hence antiviral drugs have been used to reduce the development of respiratory complications by reducing viral load. The purpose of this review is to provide a comprehensive update on the pathogenesis, clinical aspects, diagnosis, challenges and treatment of SARS-CoV-2 infections.","Pathogens","Mungroo, Mohammad Ridwane","Khan, Naveed Ahmed","Siddiqui, Ruqaiyyah","32316618"],"abstract":["Since December 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in devastating consequences worldwide and infected more than 350,000 individuals and killed more than 16,000 people. SARS-CoV-2 is the seventh member of the coronavirus family to affect humans. Symptoms of COVID-19 include fever (88%), cough (68%), vomiting (5%) and diarrhoea (3.7%), and transmission of SARS-CoV-2 is thought to occur from human to human via respiratory secretions released by the infected individuals when coughing and sneezing. COVID-19 can be detected through computed tomography scans and confirmed through molecular diagnostics tools such as polymerase chain reaction. Currently, there are no effective treatments against SARS-CoV-2, hence antiviral drugs have been used to reduce the development of respiratory complications by reducing viral load. The purpose of this review is to provide a comprehensive update on the pathogenesis, clinical aspects, diagnosis, challenges and treatment of SARS-CoV-2 infections."],"journal":"Pathogens","authors":["Mungroo, Mohammad Ridwane","Khan, Naveed Ahmed","Siddiqui, Ruqaiyyah"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32316618","week":"202017|Apr 20 - Apr 26","doi":"10.3390/pathogens9040297","keywords":["2019-ncov","covid-19","sars-cov-2","coronavirus","diagnosis","transmission","treatment"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1664815087626485760,"score":250.84253},{"pmid":32260471,"title":"In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","text":["In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19.","Diagnostics (Basel)","Vashist, Sandeep Kumar","32260471"],"abstract":["There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19."],"journal":"Diagnostics (Basel)","authors":["Vashist, Sandeep Kumar"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32260471","week":"202015|Apr 06 - Apr 12","doi":"10.3390/diagnostics10040202","keywords":["covid-19","sars-cov-2","diagnostics","immunoassays","lateral flow immunoassay (lfia)","point-of-care (poc)","real-time reverse transcriptase polymerase chain (rt-pcr)"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Abbott"],"_version_":1664637635998515201,"score":250.31996}]}